

(c) if so, the details thereof and the necessary steps taken by Government in this regard?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI HANSRAJ GANGARAM AHIR): (a) to (c) There are 22 medical devices regulated as 'drug' under the Drugs and Cosmetics Act and Rules there under. Out of 22 medical devices, 2 are under price control for which ceiling price have been notified under DPCO, 2013. NPPA has asked the manufacturer/distributor of the medical devices, regulated as drugs, to provide certain information for monitoring of price movement as non-scheduled formulations under DPCO, 2013. DPCO, 2013 provides that no manufacturer/importer or distributor is allowed to increase the MRP of a non-scheduled drug more than ten per cent of MRP during preceding twelve months and where the increase is beyond ten per cent, it shall reduce the same to the level of ten per cent of maximum retail price for next twelve months. Based on information received in Form-V of Schedule II of DPCO, 2013, it is seen that bulk of stents consumed in the country are imported and the difference between landed cost and maximum retail price (MRP) is very high. NPPA *vide* its letter dated 27.03.2015 has submitted a report to the Department on pricing of cardiac stents based on the available information and the study conducted by National Health System Resource Centre (NHSRC).

Regulatory measures by US on Indian drug exports

152. SHRI DEVENDER GOUD T: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) in view of continuous regulatory measures by US impacting Indian drug exports to US, what alternatives Indian drug manufacturing companies are looking at to stay ahead in generic medicines; and

(b) why cannot our pharma companies explore Africa, Middle East and some of the European countries?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI HANSRAJ GANGARAM AHIR): (a) In spite of stringent regulatory measures by the US, India is the 4th largest partner of USA in supply of generic medicines with over US\$ 4 billion exports to US during the year 2013-14.

(b) Indian Pharma companies are already exporting to Africa, Middle East and European countries.